Abstract
Amyloid aggregation is linked to a number of human disorders that range from non-neurological illnesses such as type 2 diabetes to neurodegenerative diseases such as Alzheimer’s and Parkinson’s diseases. The formation of insoluble protein aggregates with amyloid conformation inside bacteria, namely, in bacterial inclusion bodies, offers the possibility to use bacteria as simple models to study amyloid aggregation processes and potential effects of both anti-amyloid drugs and/or pro-aggregative compounds. This chapter describes fast, simple, inexpensive, highly reproducible, and tunable in vitro and in cellulo methods that use bacterial inclusion bodies as preliminary screening tools for anti-amyloid drugs.
Key words
- Bacterial inclusion body
- Amyloid aggregation
- Drug screening
- Conformational disease
This is a preview of subscription content, access via your institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsSpringer Nature is developing a new tool to find and evaluate Protocols. Learn more
References
Chiti F, Dobson CM (2017) Protein misfolding, amyloid formation, and human disease: a summary of progress over the last decade. Annu Rev Biochem 86:27–68
Kopito RR, Ron D (2000) Conformational disease. Nat Cell Biol 2:E207–E209
Ventura S, Villaverde A (2006) Protein quality in bacterial inclusion bodies. Trends Biotechnol 24:179–185
Mitraki A (2010) Protein aggregation. In: Advances in protein chemistry and structural biology, pp 89–125
Wang L, Maji SK, Sawaya MR et al (2008) Bacterial inclusion bodies contain amyloid-like structure. PLoS Biol 6:e195
Morell M, Bravo R, Espargaró A et al (2008) Inclusion bodies: specificity in their aggregation process and amyloid-like structure. Biochim Biophys Acta, Mol Cell Res 1783:1815–1825
Villar-Pique A, Espargaro A, Ventura S et al (2014) Screening for amyloid aggregation: in-silico, in-vitro and in-vivo detection. Curr Protein Pept Sci 15:477–489
Carrió MM, Corchero JL, Villaverde A (1999) Proteolytic digestion of bacterial inclusion body proteins during dynamic transition between soluble and insoluble forms. Biochim Biophys Acta – Protein Struct Mol Enzymol 1434:170–176
Carrió M, González-Montalbán N, Vera A et al (2005) Amyloid-like properties of bacterial inclusion bodies. J Mol Biol 347:1025–1037
Wasmer C, Benkemoun L, Sabaté R et al (2009) Solid-State NMR Spectroscopy Reveals that E. coli Inclusion Bodies of HET-s(218–289) are Amyloids. Angew Chemie Int Ed 48:4858–4860
Groot NS, Sabate R, Ventura S (2009) Amyloids in bacterial inclusion bodies. Trends Biochem Sci 34:408–416
Groot NS, Espargaró A, Morell M et al (2008) Studies on bacterial inclusion bodies. Future Microbiol 3:423–435
Dasari M, Espargaro A, Sabate R et al (2011) Bacterial inclusion bodies of Alzheimer’s disease β-amyloid peptides can be employed to study native-like aggregation intermediate states. Chembiochem 12:407–423
Gupta V, Sudhakaran IP, Islam Z et al (2020) Expression, purification and characterization of α-synuclein fibrillar specific scFv from inclusion bodies. PLoS One 15:e0241773
Swietnicki W, Petersen RB, Gambetti P et al (1998) Familial mutations and the thermodynamic stability of the recombinant human prion protein. J Biol Chem 273:31048–31052
Askanas V, Engel WK, McFerrin J et al (2003) Transthyretin Val122Ile, accumulated A, and inclusion-body myositis aspects in cultured muscle. Neurology 61:257–260
Umetsu M, Tsumoto K, Nitta S et al (2005) Nondenaturing solubilization of β2 microglobulin from inclusion bodies by l-arginine. Biochem Biophys Res Commun 328:189–197
Redwan EM, Matar SM, El-Aziz GA et al (2007) Synthesis of the human insulin gene: protein expression, scaling up and bioactivity. Prep Biochem Biotechnol 38:24–39
Li M, Su Z (2002) Refolding human lysozyme produced as an inclusion body by urea concentration and pH gradient ion exchange chromatography. Chromatographia 56:33–38
Hou X-Q, Yan R, Yang C et al (2014) A novel assay for high-throughput screening of anti-Alzheimer’s disease drugs to determine their efficacy by real-time monitoring of changes in PC12 cell proliferation. Int J Mol Med 33:543–549
Villar-Piqué A, Espargaró A, Ventura S et al (2016) In vivo amyloid aggregation kinetics tracked by time-lapse confocal microscopy in real-time. Biotechnol J 11:172–177
Cornejo A, Aguilar Sandoval F, Caballero L et al (2017) Rosmarinic acid prevents fibrillization and diminishes vibrational modes associated to β sheet in tau protein linked to Alzheimer’s disease. J Enzyme Inhib Med Chem 32:945–953
Cornejo A, Jiménez JM, Caballero L et al (2011) Fulvic acid inhibits aggregation and promotes disassembly of tau fibrils associated with Alzheimer’s disease. J Alzheimers Dis 27:143–153
Chua SW, Cornejo A, van Eersel J et al (2017) The polyphenol Altenusin inhibits in vitro fibrillization of tau and reduces induced tau pathology in primary neurons. ACS Chem Neurosci 8:743–751
Saleem S, Kannan RR (2018) Zebrafish: an emerging real-time model system to study Alzheimer’s disease and neurospecific drug discovery. Cell Death Discov 4:45
Prüßing K, Voigt A, Schulz JB (2013) Drosophila melanogaster as a model organism for Alzheimer’s disease. Mol Neurodegener 8:35
Luo Y (2006) Alzheimer’s disease, the nematode Caenorhabditis elegans, and ginkgo biloba leaf extract. Life Sci 78:2066–2072
García-Fruitõs E, Sabate R, De GNS et al (2011) Biological role of bacterial inclusion bodies: a model for amyloid aggregation. FEBS J 278:2419–2427
Carrió MM, Cubarsi R, Villaverde A (2000) Fine architecture of bacterial inclusion bodies. FEBS Lett 471:7–11
Espargaró A, Sabaté R, Ventura S (2008) Kinetic and thermodynamic stability of bacterial intracellular aggregates. FEBS Lett 582:3669–3673
Villar-Piqué A, Espargaró A, Sabaté R et al (2012) Using bacterial inclusion bodies to screen for amyloid aggregation inhibitors. Microb Cell Factories 11:1–11
Jarrett JT, Lansbury PT (1993) Seeding “one-dimensional crystallization” of amyloid: a pathogenic mechanism in Alzheimer’s disease and scrapie? Cell 73:1055–1058
Sabaté R, Gallardo M, Estelrich J (2003) An autocatalytic reaction as a model for the kinetics of the aggregation of β-amyloid. Biopolymers 71:190–195
Darghal N, Garnier-Suillerot A, Salerno M (2006) Mechanism of thioflavin T accumulation inside cells overexpressing P-glycoprotein or multidrug resistance-associated protein: role of lipophilicity and positive charge. Biochem Biophys Res Commun 343:623–629
Espargaró A, Medina A, Di PO et al (2016) Ultra rapid in vivo screening for anti-Alzheimer anti-amyloid drugs. Sci Rep 6:23349
Espargaró A, Ginex T, Vadell M et al (2017) Combined in vitro cell-based/in silico screening of naturally occurring flavonoids and phenolic compounds as potential anti-Alzheimer drugs. J Nat Prod 80:278–289
Espargaró A, Sabate R, Ventura S (2012) Thioflavin-S staining coupled to flow cytometry. A screening tool to detect in vivo protein aggregation. Mol BioSyst 8:2839
Acknowledgments
Financial support from the Spanish Ministerio de Ciencia e Innovación (Projects PID2020-115537RB-100, CTQ2017-88446-R and RED2018-102471-T; MCIN/AEI/10.13039/501100011033) is kindly acknowledged. P.G. acknowledges the Institució Catalana de Recerca i Estudis Avançats (ICREA).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Caballero, A.B., Gamez, P., Sabate, R., Espargaró, A. (2022). Anti-Amyloid Drug Screening Methods Using Bacterial Inclusion Bodies. In: Arluison, V., Wien, F., Marcoleta, A. (eds) Bacterial Amyloids. Methods in Molecular Biology, vol 2538. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-2529-3_12
Download citation
DOI: https://doi.org/10.1007/978-1-0716-2529-3_12
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-2528-6
Online ISBN: 978-1-0716-2529-3
eBook Packages: Springer Protocols